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Abstract
Although tick-borne encephalitis (TBE) has been recognized in Europe for more than 70 years and has been the topic of numerous
reports, information on the involvement of facial nerves in the course of the disease is limited. Our study conducted at a single medical
centre revealed that facial nerve involvement in the course of TBE in Central Europe is (i) infrequent—it was found in only 11 of 1218
(0.9%) consecutive adult patients diagnosed with TBE; (ii) manifests with unilateral or rarely bilateral peripheral facial palsy (PFP) (nine
and two patients, respectively); (iii) appears late in the course of acute illness—in our patients 10–20 days after the onset of the menin-
goencephalitic phase of TBE, and often after defervescence (in 8/11 patients; 6–13 days after normalization of body temperature); (iv)
develops more often in patients with more severe illness, i.e. more frequently in those with encephalitic than in those with meningitic
clinical presentation, and more commonly in patients with monophasic than biphasic illness; and (v) has a favourable outcome—our
patients had a clinically complete recovery from PFP within 7–90 (median 30) days after its onset. Moreover, the ﬁnding of Borrelia
infection in 3/11 (27.3%) patients (diagnosis of conﬁrmed Lyme neuroborreliosis was established in 1/11 patients and two patients ful-
ﬁlled criteria for possible Lyme neuroborreliosis) suggests that in countries where TBE and Lyme borreliosis are endemic, concomitant
infection with Borrelia burgdorferi sensu lato should be considered and searched for in patients who develop PFP in the course of TBE.
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The most important tick-borne diseases in Slovenia are Lyme
borreliosis and tick-borne encephalitis (TBE). Their incidence
rates are among the highest in Europe [1]. The causative
agents of the diseases—Borrelia burgdorferi sensu lato and
TBE virus (TBEV)—are transmitted by the hard tick Ixodes
ricinus, which is the prevalent tick species in Slovenia [2].
Three subtypes of TBEV (European, Siberian and Far East-
ern subtypes) that cause the disease result in similar but not
identical illnesses. More than half of patients with TBE caused
by the European subtype of TBEV have a characteristic
biphasic course of illness. The initial phase, which corre-
sponds to viraemia and lasts for 1–8 days, is characterized by
fever, headache and malaise. It is followed by an improve-
ment or even an asymptomatic interval of about 1 week, and
then by signs and symptoms of neurological involvement.
The second phase presents as meningitis, meningoencephali-
tis, or meningoencephalomyelitis in 50%, 40% and 5–10% of
adult patients, respectively. The severity of illness increases
with age: the predominant manifestation in children is menin-
gitis whereas in elderly people meningoencephalitis prevails.
The majority of patients recover completely. The reported
fatality rate of TBE in Europe is 0.5–2% [3,4].
In TBE the involvement of cranial nerves has been
reported only occasionally and in only a subset of patients
with cranial nerve involvement does facial palsy develop [5–
22]. This is in contrast to Lyme borreliosis, which has been
associated with a wide range of neurological disorders
including meningitis, cranial neuritis, radiculoneuritis, periph-
eral neuritis in association with acrodermatitis chronica
atrophicans and, rarely, meningoencephalitis and encephalop-
athy, and in which peripheral facial palsy (PFP) is common. In
fact, PFP is by far the most frequent manifestation of cranial
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nerve involvement, may be the only neurological manifesta-
tion during early disseminated borrelial infection, may
develop without antecedent erythema migrans, sometimes
before measurable antibody response, and is, as a rule, asso-
ciated with cerebrospinal ﬂuid (CSF) pleocytosis [23]. Con-
comitant infections with B. burgdorferi sensu lato and TBEV
have been reported [24]. Hence, at least in some patients
PFP that develops in the course of TBE might have been the
result of a concomitant borrelial infection. According to a lit-
erature review, this potential correlation has not been tested
systematically.
The purpose of this study was to establish the frequency
and characteristics of facial palsy in adult patients with TBE
and to assess the occurrence of borrelial infection in the
group of patients who develop PFP in the course of TBE.
Patients and Methods
At our institution, a regular initial approach in all patients
with clinical signs/symptoms indicating meningitis or meningo-
encephalitis is to obtain a detailed epidemiological and medi-
cal history, to perform physical examination, to carry out
routine blood and CSF tests including cell counts, concentra-
tion of total proteins, glucose, albumin, IgG, IgA and IgM, as
well as to test for infection with TBEV and B. burgdorferi
sensu lato. After hospitalization, patients with TBE are fol-
lowed for at least 8 weeks whereas those in whom borrelial
infection is demonstrated are generally followed for 1 year.
All patients older than 15 years with TBE, hospitalized at
the Department of Infectious Diseases, University Medical
Centre Ljubljana, Slovenia, during the period from January
2003 to December 2009, in whom facial palsy developed
during their illness, were included in the present study.
The presence of serum IgM and IgG antibodies against
TBEV was determined using the Enzygnost Anti-TBEV
(IgM, IgG) test (Dade Behring Marburg GmbH, Marburg,
Germany) performed according to the manufacturer’s
instructions.
The course of illness in patients with TBE and associated
facial palsy was compared with the course in patients with
TBE without facial palsy. For each patient with TBE associ-
ated with facial palsy, ten other patients diagnosed with TBE
at our institution in the same year, and who were of the
same sex and the most comparable age, were included in the
control group.
All of these patients were routinely tested for borrelial
infection at presentation (serum and CSF borrelial antibod-
ies, culture of CSF) and 6–8 weeks later (determination of
borrelial antibodies in serum). Borrelial serum and CSF IgM
and IgG antibody titres were determined by an in-house
indirect immunoﬂuorescence assay using a local skin isolate
of Borrelia afzelii for antigen [25]. Serum antibody titres
‡1 : 256 and CSF antibody titres ‡1 : 16 were interpreted
as positive. Intrathecal speciﬁc antibody synthesis was
assessed by calculation of IgM and IgG antibody index. Val-
ues >2 were interpreted as indicative for intrathecal anti-
body production [26].
The CSF specimens were cultured for the presence of
Borrelia in modiﬁed Kelly–Pettenkofer medium. Specimens
were incubated at 33C and checked weekly for the pres-
ence of Borrelia for 9 weeks. The species of the isolated Bor-
relia strains were identiﬁed by polymerase chain reaction or
by pulsed-ﬁeld gel electrophoresis after restriction by MluI
restriction enzyme as reported previously [25].
Case deﬁnitions
Diagnosis of TBE was considered to be conﬁrmed by the fol-
lowing ﬁndings: fever, clinical signs/symptoms of meningitis
or meningoencephalitis, an elevated CSF leucocyte count
(>5 · 106/L) and the presence of serum IgM and IgG anti-
bodies to TBEV. The TBE was assessed clinically as mild
(only signs/symptoms of meningeal involvement), moderate
(monofocal neurological signs and/or mild to moderate signs/
symptoms of central nervous system dysfunction) or severe
(multifocal neurological signs and/or signs/symptoms of
severe dysfunction of central nervous system).
Lyme neuroborreliosis was interpreted as being conﬁrmed
by elevated CSF cell counts and the isolation of B. burgdorferi
sensu lato from CSF, and/or demonstration of intrathecal
borrelial antibody production, and/or seroconversion to bor-
relial antigens. In patients with positive but unchanging borre-
lial serum antibody titres and without other previously
mentioned microbiological criteria, the diagnosis of Lyme
neuroborreliosis was considered possible.
Data analysis
Categorical data were analysed with Yates’ corrected chi-
square test or Fisher’s exact test (two-tailed), whereas quan-
titative data were analysed by the Kruskal–Wallis test, using
EPI INFO version 3.4.3. software (Centers for Disease Con-
trol, Atlanta, GA, USA). A p value <0.05 was interpreted as
statistically signiﬁcant.
Results
Of 1218 adult patients (705 males, 513 females; median age
56 years, range 15–91 years), diagnosed with TBE at our
department from 2003 to 2009, 11 (0.9%) developed PFP
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during the course of their illness—two had bilateral and nine
had unilateral facial nerve involvement—central facial palsy
was not found.
In the group of 11 patients with PFP there were ten men
and one woman, with a median age of 53 years (range, 41–
76 years). Eight (72.7%) patients had a monophasic course of
TBE and only three (27.3%) patients had a biphasic course of
TBE. The illness was relatively mild in one (9.1%) patient
who presented with signs/symptoms of meningitis, moder-
ately severe in nine (81.8%) patients with signs/symptoms of
meningoencephalitis, and severe in one (9.1%) patient with
meningoencephalomyelitis who had pronounced conscious-
ness disturbances and required mechanical ventilation. In the
last patient, severe pain in the shoulders preceded paresis of
shoulder muscles, which appeared on the 8th day of his ill-
ness and was followed by bilateral facial palsy 9 days later
(17th day of the illness).
One of the 11 patients developed TBE in spite of com-
plete vaccination; he received the third dose of basic vaccina-
tion against TBE 4 years before the onset of his illness,
which had a relatively mild course. In this 41-year-old patient
the diagnosis of TBE was ascertained by demonstration of
intrathecal synthesis of speciﬁc IgG antibodies.
Facial nerve involvement appeared 15 (6–30) days after
the beginning of TBE (deﬁned as the ﬁrst day of fever),
and 12 (10–20) days after the onset of the meningoen-
cephalitic phase of the illness. In eight (72.7%) patients (in
6/8 with monophasic disease and in 2/3 with a biphasic
course of TBE) PFP developed in the afebrile period, i.e.
10 (6–13) days after defervescence. All the patients had a
clinically complete recovery of PFP within 7–90 (median
30) days after its onset. Patients were hospitalized for
median 9 (range 6–34) days. None of them died during
acute illness.
At admission to hospital, serum borrelial immunoﬂuores-
cent assay IgG antibody titre ‡1 : 256 was found in two
(18.2%) patients, whereas in one (9.1%) seronegative patient,
who satisﬁed criteria for conﬁrmed Lyme neuroborreliosis,
B. afzelii was isolated from the CSF. All three patients had
unilateral PFP, were treated with intravenous ceftriaxone
2 g/day for 14 days, and had an uneventful outcome. The
duration of PFP in patients with TBE and associated Lyme
neuroborreliosis was comparable to the duration of PFP in
TBE patients without borrelial co-infection: 30 (14–30) days
versus 37.5 (7–90) days, respectively; p 0.532.
Basic demographic and clinical characteristics for 11
patients with TBE in whom PFP developed in the course of
their illness and 110 sex-matched and age-matched control
patients who were diagnosed with TBE without PFP in the
same year, are depicted in Table 1.
Patients with TBE and associated PFP did not differ signiﬁ-
cantly from control subjects for the majority of basic demo-
graphic and clinical ﬁndings (Table 1) as well as the
frequency of demonstration of Borrelia infection (Table 2).
However, a higher proportion of patients with meningo-
encephalitis/meningoencephalomyelitis (90.9% versus 56.4%;
p 0.028) as well as a higher ratio of patients who received
anti-oedematous treatment (63.6% versus 24.5%; p 0.011)
indicate that among the patients who develop PFP in the
course of TBE, the acute illness was more severe than in
those without facial nerve involvement (Table 1).
TABLE 1. Comparison of basic demographic and clinical
ﬁndings for 11 patients who develop peripheral facial palsy
in the course of tick-borne encephalitis, and 110 patients





PFP n (%) p
Patient sex: female/male 1 (9.1)/10 (90.9) 10 (9.1)/100 (90.9) 1.000a
Age (years): median (range) 53 (41–76) 54 (41–76) 0.642b
Tick bitec 9 (81.8) 72 (65.5) 0.335a
>1 tick bite 4/9 (44.4) 28/72 (38.9) 0.734a
Biphasic course of TBE 3 (27.3) 54 (49.1) 0.287a
Severity of TBE:
Mild 1 (9.1) 48 (43.6) 0.028a
Moderate 9 (81.8) 56 (50.9) 0.100a
Severe 1 (9.1) 6 (5.5) 0.496a
Anti-oedematous treatmentd 7 (63.6) 27 (24.5) 0.011a
aDetermined by Yates corrected chi-square test or Fisher¢s exact test (two--
tailed).
bDetermined by Kruskal–Wallis test.
cTick bite recalled within 6 weeks before the onset of illness.
dPatients were treated by 20% manitol followed by furosemid.
PFP, peripheral facial palsy; TBE, tick-borne encephalitis.
TABLE 2. Comparison of Borrelia serological testing results,
intrathecal borrelial antibody production and isolation of
Borrelia from cerebrospinal ﬂuid in 11 patients with tick-
borne encephalitis and peripheral facial palsy, and 110






PFP n (%) pa
Immunoﬂuorescence assay
Serum IgG (‡1 : 256) 2 (18.2) 7 (6.4) 0.190
CSF IgG (‡1:16) 0 1 (0.9) 1.000
Intrathecal IgG antibody
production (Index >2)
0 1 (0.9)b 1.000
Isolation of Borrelia from CSF 1 (9.1)c 1 (0.9)d 1.174
Any indication of Borrelia infection 3 (27.3) 9 (8.2) 0.078
aDetermined by Yates corrected chi-square test or Ficher¢s exact test (two-
tailed).
bCSF IgG antibody borrelial index was 4.25.
cBorrelia afzelii was identiﬁed.
dBorrelia garinii was identiﬁed.
CSF, cerebrospinal ﬂuid; IFA, in-house indirect immunoﬂuorescence assay; PFP,
peripheral facial palsy; TBE, tick-borne encephalitis.
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Discussion
Although TBE has been recognized in Europe for more than
70 years, has been of public health importance in several
countries [27], and has been the topic of numerous reports,
relatively little is known about the involvement of cranial
nerves in the course of the illness. Acute involvement of
most cranial nerves with often favourable outcome has been
described; it was mainly associated with the impairment of
ocular, facial and pharyngeal motor function, but vestibular
and hearing defects were also encountered [3,4]. Concerning
the facial nerve, it is evident that it can be involved; how-
ever, the type of impairment, the frequency of the damage,
the circumstances in which it occurs and when in the course
of the illness it appears, are less clear. Among case series
consisting of more than 100 patients with TBE that were
published during the last 50 years [5–22], we were able
to ﬁnd 13 articles with data on cranial nerve involvement
[5,7–18], including nine reports with information on facial
nerve damage (Table 3). In these case series cranial nerve
involvement was found in 0.8–11% of patients and facial palsy
in 0.8–2.6% of patients. However, in the majority of the
articles the information on cranial nerve involvement was
superﬁcial. For example, in patients reported to have facial
nerve damage, data enabling unambiguous differentiation
between upper and lower motor neuron involvement were
not available. Our review of 1218 adult patients diagnosed
with TBE during the 7 years of the study revealed 11 (0.9%)
patients with facial nerve involvement; all of them had PFP.
Information from the literature suggests that the occur-
rence of cranial nerve involvement varies with the severity
of clinical presentation of TBE. Mickiene et al. [12]
reported cranial nerve injury (no case of facial involve-
ment) in 5.3% (7/133) of patients in the acute stage of
TBE; the majority of them had the severe form of the dis-
ease. Haglund et al. [9] found unilateral facial palsy in only
one out of 114 patients with TBE; the patient had a very
severe illness with tetraparesis and unfavourable outcome.
Kaiser [10] established involvement of cranial nerves in
11% of 656 patients with TBE. Facial palsy was present in
2.6% (17/656) of patients and its frequency ranked second
after the impairment of nervus vestibularis. It was found in
3% of patients with meningitis, in 2.6% of patients with
meningoencephalitis, and in 15.1% of patients with men-
ingoencephalomyelitis. Facial palsy was more frequently
established in adults than in children. In a few studies in
which only children with TBE were included, facial palsy
was very rare and as a rule developed in patients with
the severe course of the disease [11,14,16].
TABLE 3. Information on the frequency of cranial nerve involvement in European patients with tick-borne encephalitis
(reports with >100 patients are shown)
Reference
No. of patients with TBE
(No. of analysed)
No. (%) of patients with
cranial nerve involvement
Affected cranial nerves except
VIIth No. (%) of patients
No. (%) of patients
with facial palsy
Duniewicz et al. [5] 633a 29 (4.6) III 3 (0.5)
VIII 2 (0.3)
IX, X, XI 10 (1.6)
VII 14 (2.2)
Radsel-Medvescek et al. [7] 315a 11 (3.5) NA NA
Wahlberg et al. [8] 126a 2 (1.6) NA 2 (1.6)
Haglund et al. [9] 143 (114)b 1 (0.9) 0 1 (0.9)








Cˇizˇman et al. [11] 133d 1(0.8)c 0 1 (0.8)
Mickiene et al. [12] 133b 7 (5.3) NA NA
Grygorczuk et al. [13] 152b 5 (3.3)c III 2 (1.3)
IX, X 1 (0.7)
2 (1.3)
Lesnicar et al. [14] 371d 14 (3.8) NA 1 (0.3)
Logar et al. [15] 448b 5 (1.1) NA NA
Fritsch et al. [16] 116d 2 (1.7) 0 2 (1.7)
Misˇic´-Majerus et al. [17] 133 (124)b 11 (8.8) NA NA







aAdults and children are included.
bOnly adults are included.
cIn some patients more than one cranial nerve was affected.
dOnly children are included.
NA, not available.
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Our results further corroborate published information on
the association of PFP and the severity of TBE. Comparison
of the 11 patients with TBE in whom PFP developed during
the course of their illness and 110 sex-matched and age-
matched control patients who were diagnosed with TBE but
without PFP in the same year (Table 1) revealed a higher
proportion of patients with meningoencephalitis/mening-
oencephalomyelitis (90.9% versus 56.4%; p 0.028) as well as
a higher ratio of patients who received anti-oedematous
treatment (63.6% versus 24.5%; p 0.011) in the group of
patients with PFP. These ﬁndings indicate that in the group
of patients with TBE and PFP the acute illness is more severe
than in those without facial nerve involvement. In addition,
the majority of our patients with PFP (8/11) had a monopha-
sic course of TBE; according to some authors monophasic
presentation is associated with a more severe acute course
of the disease [3,8,20–22,28].
In our group of 11 patients with TBE and PFP facial nerve
damage appeared late in the course of TBE, median 12 (10–
20) days after the onset of the meningoencephalitic phase of
the illness, in the majority of patients (8/11, 72.7%) in a feb-
rile period, i.e. 10 (6–13) days after defervescence. These
ﬁndings are comparable to the results of Duniewicz et al. [5]
who reported that facial palsy developed more often after
defervescence (10/14, 71.4%) than during the febrile phase of
acute disease. They point to the need for clinical follow up
of patients with TBE and pose further questions about the
pathogenesis of this rare manifestation, which remains to be
elucidated. A simple clinical approach that was used in our
study does not enable an insight into the pathogenesis of
PFP. However, a ﬁnding that one of our patients with TBE
and PFP was vaccinated against TBE might indicate that the
presence of antibodies induced by vaccine could potentially
have been associated with the development of PFP. It has
been known that the presence of a speciﬁc antibody may
enhance disease symptoms for a variety of viruses including
dengue virus and also TBEV [29].
The ﬁndings of the present study indicate that some
patients with TBE also have borrelial infection. The diagnosis
of conﬁrmed Lyme neuroborreliosis was established in one
of 11 (9.1%) patients in whom PFP developed in the course
of TBE whereas two (18.2%) patients fulﬁlled the criteria for
possible Lyme neuroborreliosis (Table 2). All three patients
had unilateral PFP, were treated with intravenous ceftriaxone
2 g/day for 14 days, and had an uneventful outcome. The
duration of PFP in patients with TBE and associated Lyme
neuroborreliosis was comparable to the duration of PFP in
TBE patients without borrelial co-infection. The diagnosis of
borrelial infection is important because patients with PFP in
association with Lyme borreliosis should receive antibiotic
therapy, not primarily for the purpose of expediting recovery
from the paralysis, which will usually resolve within a few
weeks regardless of whether antimicrobial therapy is given,
but rather to prevent later complications [30].
In conclusion, facial nerve involvement in the course of
TBE in Central Europe is infrequent, manifests with unilateral
or rarely bilateral PFP, appears late in the course of acute
illness (quite often after defervescence) and more often in
patients with encephalitic that in those with meningitis clini-
cal presentation, and has a favourable outcome. In European
countries, where TBE and Lyme borreliosis are endemic,
such as Slovenia, concomitant infection with B. burgdorferi
sensu lato should be considered and searched for in patients
who developed PFP in the course of TBE.
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